(Press-News.org) by Prof Heidi Newberg
The Earth supports the only known life in the universe, all of it depending heavily on the presence of liquid water to facilitate chemical reactions. While single-celled life has existed almost as long as the Earth itself, it took roughly three billion years for multicellular life to form. Human life has existed for less than one 10 thousandth of the age of the Earth.
All of this suggests that life might be common on planets that support liquid water, but it might be uncommon to find life that studies the universe and seeks to travel through space, like we do. To find extraterrestrial life, it might be necessary for us to travel to it.
However, the vastness of space, coupled with the impossibility of traveling or communicating faster than the speed of light, places practical limits on how far we can roam. Only the closest stars to the sun could possibly be visited in a human lifetime, even by a space probe. In addition, only stars similar in size and temperature to the sun are long-lived enough, and have stable enough atmospheres, for multicellular life to have time to form. For this reason, the most valuable stars to study are the 60 or so sun-like stars that are closer to us than approximately 30 light-years. The most promising planets orbiting these stars would have sizes and temperatures similar to the Earth, so solid ground and liquid water can exist.
A needle in the haystack
Observing an Earth-like exoplanet separately from the star it is orbiting around is a major challenge. Even in the best possible scenario, the star is a million times brighter than the planet; if the two objects are blurred together, there is no hope of detecting the planet. Optics theory says that the best resolution one can get in telescope images depends on the size of the telescope and the wavelength of the observed light. Planets with liquid water give off the most light at wavelengths around 10 microns (the width of a thin human hair and 20 times the typical wavelength of visible light). At this wavelength, a telescope needs to collect light over a distance of at least 20 meters to have enough resolution to separate the Earth from the sun at a distance of 30 light-years. Additionally, the telescope must be in space, because looking through the Earth’s atmosphere would blur the image too much. However, our largest space telescope – the James Webb Space Telescope (JWST) – is only 6.5 meters in diameter, and that telescope was extremely difficult to launch.
Because deploying a 20-meter space telescope seems out-of-reach with current technology, scientists have explored several alternative approaches. One involves launching multiple, smaller telescopes that maintain extremely accurate distances between them, so that the whole set acts as one telescope with a large diameter. But, maintaining the required spacecraft position accuracy (which must be precisely calibrated to the size of a typical molecule) is also currently infeasible.
Other proposals use shorter wavelength light, so that a smaller telescope can be used. However, in visible light a sun-like star is more than 10 billion times brighter than the Earth. It is beyond our current capability to block out enough starlight to be able to see the planet in this case, even if in principle the image has high enough resolution.
One idea for blocking the starlight involves flying a spacecraft called a ‘starshade’ that is tens of meters across, at a distance of tens of thousands of miles in front of the space telescope, so that it exactly blocks the light from the star while the light from a companion planet is not blocked. However, this plan requires that two spacecraft be launched (a telescope and a starshade). Furthermore, pointing the telescope at different stars would entail moving the starshade thousands of miles, using up prohibitively large quantities of fuel.
A rectangular perspective
In our paper, we propose a more feasible alternative. We show that it is possible to find nearby, Earth-like planets orbiting sun-like stars with a telescope that is about the same size as JWST, operating at roughly the same infrared (10 micron) wavelength as JWST, with a mirror that is a one by 20 meter rectangle instead of a circle 6.5 meters in diameter.
With a mirror of this shape and size, we can separate a star from an exoplanet in the direction that the telescope mirror is 20 meters long. To find exoplanets at any position around a star, the mirror can be rotated so its long axis will sometimes align with the star and planet. We show that this design can in principle find half of all existing Earth-like planets orbiting sun-like stars within 30 light-years in less than three years. While our design will need further engineering and optimization before its capabilities are assured, there are no obvious requirements that need intense technological development, as is the case for other leading ideas.
If there is about one Earth-like planet orbiting the average sun-like star, then we would find around 30 promising planets. Follow-up study of these planets could identify those with atmospheres that suggest the presence of life, for example oxygen that was formed through photosynthesis. For the most promising candidate, we could dispatch a probe that would eventually beam back images of the planet’s surface. The rectangular telescope could provide a straightforward path towards identifying our sister planet: Earth 2.0.
END
Circle versus rectangle: Finding ‘Earth 2.0’ may be easier using a new telescope shape
Guest editorial by Prof Heidi Newberg, an astrophysicist at Rensselaer Polytechnic Institute and author of a new Frontiers in Astronomy and Space Sciences article
2025-09-01
ELSE PRESS RELEASES FROM THIS DATE:
Metformin changes blood metal levels in humans
2025-09-01
The widely used diabetes drug metformin changes blood metal levels in humans. The Kobe University study is an important step in understanding the drug’s many actions and designing better ones in the future.
Metformin is the most widely prescribed diabetes drug in the world. Apart from lowering blood sugar levels, it is also known to have a broad range of beneficial side effects such as against tumors, inflammations and atherosclerosis. However, although it has been used for more than 60 years ...
Long-term anticoagulation discontinuation after catheter ablation for atrial fibrillation
2025-08-31
About The Study: Among patients without documented atrial arrhythmia recurrence after catheter ablation for atrial fibrillation, discontinuing oral anticoagulant therapy resulted in a lower risk for the composite outcome of stroke, systemic embolism, and major bleeding vs continuing direct oral anticoagulant therapy.
Corresponding Author: To contact the corresponding author, Boyoung Joung, MD, email cby6908@yuhs.ac.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
Editor’s Note: Please see the article for additional information, including other authors, author contributions and ...
Fractional flow reserve–guided complete vs culprit-only revascularization in non–ST-elevation myocardial infarction and multivessel disease
2025-08-31
About The Study: Fractional flow reserve-guided complete revascularization during the index procedure resulted in a significant reduction in the composite of all-cause death, nonfatal myocardial infarction, any revascularization, and stroke at 1 year. This was mainly driven by reduced repeat revascularization.
Corresponding Author: To contact the corresponding author, Tobias F. S. Pustjens, MD, email t.pustjens@gmail.com.
To access the embargoed study: Visit our For The Media website at this link ...
Participation of women in cardiovascular trials from 2017 to 2023
2025-08-31
About The Study: The findings of this study highlight both progress and persistent challenges in representation of women within cardiovascular trials. These gaps not only limit the generalizability of trial outcomes but also perpetuate inequities in evidence-based care for women with cardiovascular conditions.
Corresponding Author: To contact the corresponding author, Martha Gulati, MD, MS, email martha.gulati@csmc.edu.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
Editor’s Note: Please see the article for ...
Semaglutide and tirzepatide in patients with heart failure with preserved ejection fraction
2025-08-31
About The Study: In patients with cardiometabolic heart failure with preserved ejection fraction, semaglutide and tirzepatide showed more than 40% risk reduction for the composite of hospitalization for heart failure or all-cause mortality compared with a placebo proxy. Tirzepatide showed no meaningful benefit over semaglutide.
Corresponding Author: To contact the corresponding author, Nils Krüger, MD, email nkruger1@bwh.harvard.edu.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
Editor’s Note: Please ...
Changes in biology of internal fat may be the leading cause of heart failure
2025-08-31
Heart failure with preserved ejection fraction (HFpEF) appears to develop as a result of changes in the biology of a person’s internal fat tissue, according to the Adipokine Hypothesis, a new way of understanding how fat may impact the heart. The hypothesis paper was published today in JACC, the flagship journal of the American College of Cardiology, and is being presented at ESC Congress 2025. The author of the paper is Milton Packer, MD, FACC, Distinguished Scholar in Cardiovascular Science at Baylor University Medical Center at Dallas and Visiting Professor at Imperial College in London.
“Up ...
Transcatheter or surgical treatment of patients with aortic stenosis at low to intermediate risk
2025-08-30
About The Study: In this individual participant data meta-analysis of 4 randomized clinical trials (RCTs), and an overall meta-analysis of 8 RCTs of patients with severe symptomatic aortic stenosis at low to intermediate risk, transcatheter aortic valve implantation (TAVI) was associated with a reduction in the 1-year incidence of all-cause death or any stroke. These findings emphasize TAVI as alternative option in patients at low to intermediate risk. Long-term follow-up is warranted to evaluate sustainability of these findings.
Corresponding Authors: To contact the corresponding authors, email Moritz Seiffert, MD, (moritz.seiffert@bergmannsheil.de) and ...
Promising new drug for people with stubborn high blood pressure
2025-08-30
A new treatment has been shown to significantly lower blood pressure in people whose levels stay dangerously high, despite taking several existing medicines, according to the results of a Phase III clinical trial led by a UCL Professor.
Globally around 1.3 billion people have high blood pressure (hypertension), and in around half of cases the condition is uncontrolled or treatment resistant. These individuals face a much greater risk of heart attack, stroke, kidney disease, and early death. In the UK the number of people with hypertension is around 14 ...
One shot of RSV vaccine effective against hospitalization in older adults for two seasons
2025-08-30
One shot of an RSV vaccine protects adults ages 60 or older from RSV-associated hospitalization and critical illness during two consecutive RSV seasons, according to a study published in JAMA today by the IVY Network research group.
RSV causes substantial seasonal illness during fall and winter in the U.S., with an estimated 100,000-150,000 hospitalizations and 4,000-8,000 deaths occurring annually among adults 60 or older.
The results reinforce the recommendations for RSV vaccines in older adults and lay the groundwork for understanding how long a single dose of the vaccine may be effective, ...
Bivalent RSV prefusion F protein–based vaccine for preventing cardiovascular hospitalizations in older adults
2025-08-30
About The Study: In adults age 60 or older, all-cause cardiorespiratory hospitalization was significantly lower with respiratory syncytial virus (RSV) prefusion F protein than with no vaccine. The findings suggest potential downstream cardiorespiratory benefits of RSV immunization, although the effect on all-cause cardiovascular hospitalization was not statistically significant.
Corresponding Author: To contact the corresponding author, Tor Biering-Sørensen, MD, MSc, MPH, PhD, email tor.biering@gmail.com.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
Editor’s ...
LAST 30 PRESS RELEASES:
GaN-based electron beam technology from Nagoya University startup poised to overcome critical semiconductor manufacturing challenges at KIOXIA
Circle versus rectangle: Finding ‘Earth 2.0’ may be easier using a new telescope shape
Metformin changes blood metal levels in humans
Long-term anticoagulation discontinuation after catheter ablation for atrial fibrillation
Fractional flow reserve–guided complete vs culprit-only revascularization in non–ST-elevation myocardial infarction and multivessel disease
Participation of women in cardiovascular trials from 2017 to 2023
Semaglutide and tirzepatide in patients with heart failure with preserved ejection fraction
Changes in biology of internal fat may be the leading cause of heart failure
Transcatheter or surgical treatment of patients with aortic stenosis at low to intermediate risk
Promising new drug for people with stubborn high blood pressure
One shot of RSV vaccine effective against hospitalization in older adults for two seasons
Bivalent RSV prefusion F protein–based vaccine for preventing cardiovascular hospitalizations in older adults
Clonal hematopoiesis and risk of new-onset myocarditis and pericarditis
Risk of myocarditis or pericarditis with high-dose vs standard-dose influenza vaccine
High-dose vs standard-dose influenza vaccine and cardiovascular outcomes in older adults
Prevalence, determinants, and time trends of cardiovascular health in the WHO African region
New study finds that, after a heart attack, women have worse prognosis when treated with beta-blockers
CNIC-led REBOOT clinical trial challenges 40-year-old standard of care for heart attack patients
Systolic blood pressure and microaxial flow pump–associated survival in infarct-related cardiogenic shock
Beta blockers, the standard treatment after a heart attack, may offer no benefit for heart attack patients and women can have worse outcomes
High Mountain Asia’s shrinking glaciers linked to monsoon changes
All DRII-ed up: How do plants recover after drought?
Research on stigma says to just ‘shake it off’
Scientists track lightning “pollution” in real time using NASA satellite
Millions of women rely on contraceptives, but new Rice study shows they may do more than just prevent pregnancy
Hot days make for icy weather, Philippine study finds
Roxana Mehran, MD, receives the most prestigious award given by the European Society of Cardiology
World's first clinical trial showing lubiprostone aids kidney function
Capturing language change through the genes
Public trust in elections increases with clear facts
[Press-News.org] Circle versus rectangle: Finding ‘Earth 2.0’ may be easier using a new telescope shapeGuest editorial by Prof Heidi Newberg, an astrophysicist at Rensselaer Polytechnic Institute and author of a new Frontiers in Astronomy and Space Sciences article